A Phase 3 interventional study of pregabalin and placebo in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 52 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.
Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 8th largest by enrollment, is one of 4 that started in 2011, is one of 13 in phase 3, and was the 16th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 14 · Phase 4 7
First in 2004; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 441 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 199 across the 30 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
19 studies in Fibromyalgia by Viatris Inc.: none open now, none under way, none of them phase 3. Of 19 finished, 13 (68%) have results posted.
Among the 19 studies in Fibromyalgia by Viatris Inc., this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2011, is one of 13 in phase 3, and was the 15th registered.
Viatris Inc.’s Fibromyalgia studies by the year they started, since 2004.
4 of the studies testing pregabalin in Fibromyalgia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186751Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07230197Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Dexmedetomidine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07208357Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Toludesvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
| NCT07171320Beijing Tiantan HospitalThe Efficacy and Safety of Pregabalin Combined With Desvenlafaxine in Patients With Fibromyalgia | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies testing pregabalin in Fibromyalgia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 19 in Fibromyalgia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia. All patients will receive pregabalin; half of the patients will receive placebo at some point in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: pregabalin
Drug: placebo
controlled release tablet; 165-495 mg/day; given once daily
matching placebo tablet; given once daily
Double-Blind Phase: Time to Loss of Therapeutic Response (LTR)
The time to loss of therapeutic response (LTR) is the time to loss of pain response (\<30% pain response relative to the single-blind (SB) baseline mean pain) or withdrawal due to lack of efficacy or adverse events (in the double blind phase).
Time frame: Randomization to Week 19
Double-Blind Phase: Number of Participants With Loss of Therapeutic Response (LTR) Event
Participants who did not maintain at least 30% pain response during the DB phase relative to baseline or were discontinued during DB due to lack of efficacy or an adverse event were considered to have a loss of therapeutic response.
Time frame: Randomization to Week 19
Single-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 1, 2, 3, 4, 5, 6
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6
Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).
Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Double Blind Endpoint Visit
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).
Time frame: Baseline, Double blind endpoint visit (Week 19)
Single-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Weeks 1, 2, 3, 4, 5, 6
The tiredness assessment in the daily interactive voice response system (IVRS) diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6
Double-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
The tiredness assessment in the daily IVRS diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).
Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Double-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Double Blind Endpoint Visit
The tiredness assessment in the daily IVRS diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).
Time frame: Baseline, Double blind endpoint visit (Week 19)
Single-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep and Subjective Latency to Sleep Onset at Weeks 1, 2, 3, 4, 5, 6
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6
Single-Blind Phase: Change From Baseline in Daily SSQ - Subjective Number of Awakenings After Sleep Onset at Weeks 1, 2, 3, 4, 5, 6
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6
Single-Blind Phase: Change From Baseline in Daily SSQ - Subjective Total Sleep Time at Weeks 1, 2, 3, 4, 5, 6
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6
Single-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Weeks 1, 2, 3, 4, 5, 6
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses at each week was therefore 0 (very poor) -10 (excellent), where higher scores indicated better quality of sleep.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, 6
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset and Subjective Latency to Sleep Onset at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Subjective total sleep time was the subjective estimate of the total amount of time the participant was asleep after lights out until final awakening.
Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses at each week was therefore 0 (very poor) -10 (excellent), where higher scores indicated better quality of sleep.
Time frame: Baseline, Weeks 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Wake After Sleep Onset and Subjective Latency to Sleep Onset at Double Blind Endpoint Visit
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
Time frame: Baseline, Double blind endpoint visit (Week 19)
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Double Blind Endpoint Visit
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
Time frame: Baseline, Double blind endpoint visit (Week 19)
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Double Blind Endpoint Visit
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
Time frame: Baseline, Double blind endpoint visit (Week 19)
Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Double Blind Endpoint Visit
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent).
Time frame: Baseline, Double blind endpoint visit (Week 19)
Single-Blind Phase: Change From Baseline in Weekly Pain Score at Week 6 (1 Week Recall Period)
Weekly pain scores were calculated from the daily pain diary. Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).
Time frame: Baseline, Week 6
Double-Blind Phase: Change From Baseline in Weekly Pain Score at Week 19 (1 Week Recall Period)
Weekly pain scores were calculated from the daily pain diary. Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).
Time frame: Baseline, Week 19
Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6 - Sleep Disturbance, Snoring, Awakening Short of Breath or With a Headache, Sleep Adequacy, Somnolence, Sleep Problems Index I and Sleep Problems Index II
The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.
Time frame: Baseline, Week 6
Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6- Quantity of Sleep
The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.
Time frame: Baseline, Week 6
Double-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19-Sleep Disturbance, Snoring, Awakening Short of Breath or With a Headache, Sleep Adequacy, Somnolence, Sleep Problems Index I and Sleep Problems Index II
The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.
Time frame: Baseline, Week 19
Double-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19- Quantity of Sleep
The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.
Time frame: Baseline, Week 19
Single-Blind Phase: Number of Participants Who Reported Global Impression of Change (PGIC) at Week 6
PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).
Time frame: Week 6
Double-Blind Phase: Number of Participants Who Reported Global Impression of Change (PGIC) at Week 19
PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).
Time frame: Week 19
Single-Blind Phase: Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 6
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100. Higher scores indicated a better health-related quality of life.
Time frame: Baseline, Week 6
Double-Blind Phase: Change From Baseline in SF-36 Score at Week 19
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100. Higher scores indicated a better health-related quality of life.
Time frame: Baseline, Week 19
Single-Blind Phase: Change From Baseline in Hospital Anxiety and Depression Scale (HADS) at Week 6
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Time frame: Baseline, Week 6
Double-Blind Phase: Change From Baseline in HADS Score at Week 19
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
Time frame: Baseline, Week 19
Single-Blind Phase: Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Week 6
The FIQ is a 20-item self-administered questionnaire. FIQ contains 10 subscales, which are combined to yield a total score. There are 11 questions that are related specifically to physical functioning (item 1). The remaining questions assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. The FIQ is scored from 0 to 100, with higher scores indicating more impairment.
Time frame: Baseline, Week 6
Double-Blind Phase: Change From Baseline in FIQ Score at Week 19
The FIQ is a 20-item self-administered questionnaire. FIQ contains 10 subscales, which are combined to yield a total score. There are 11 questions that are related specifically to physical functioning (item 1). The remaining questions assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. The FIQ is scored from 0 to 100, with higher scores indicating more impairment.
Time frame: Baseline, Week 19
Single-Blind Phase: Change From Baseline in Multidimensional Fatigue Inventory (MFI) at Week 6
The MFI is a 20-item, self-administered questionnaire designed to measure the following dimensions of fatigue: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Items are summed to form subscale scores; there is no overall score. The score range is from 4 to 20, where higher scores indicate greater dysfunction.
Time frame: Baseline, Week 6
Double-Blind Phase: Change From Baseline in MFI Score at Week 19
The MFI is a 20-item, self-administered questionnaire designed to measure the following dimensions of fatigue: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Items are summed to form subscale scores; there is no overall score. The score range is from 4 to 20, where higher scores indicate greater dysfunction.
Time frame: Baseline, Week 19
Single-Blind Phase: Number of Participants With Benefit, Satisfaction, Willingness to Continue Measure (BSW) at Week 6
The questionnaire consists of 3 single-item measures designed to captures the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.
Time frame: Week 6
Double-Blind Phase: Number of Participants With Benefit, Satisfaction, and Willingness (BSW) to Continue Data at Visit 9 (3 Component Questions) at Week 19
The questionnaire consists of 3 single-item measures designed to captures the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.
Time frame: Week 19
Single-Blind Phase: Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire at Week 6
WPAI: 6 question participant rated questionnaire to determine the degree to which disease state affected work productivity while at work and affected activities outside of work. Subscale scores include percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.
Time frame: Baseline, Week 6
Double-Blind Phase: Change From Baseline WPAI Questionnaire at Week 19
WPAI: 6 question participant rated questionnaire to determine the degree to which disease state affected work productivity while at work and affected activities outside of work. Subscale scores include percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.
Time frame: Baseline, Week 19
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Double Blind End Point Visit (Week 19)
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.
Time frame: Baseline, Double blind end point visit (Week 19)
Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Sleep Time at Weeks 3, 4, 5, 6 and 7
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.
Time frame: Baseline, Weeks 3, 4, 5, 6 and 7
Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Weeks 3, 4, 5, 6 and 7
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).
Time frame: Baseline, Weeks 3, 4, 5, 6 and 7
Single-Blind Phase: Change From Baseline at in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index Weeks 3, 4, 5, 6 and 7
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.
Time frame: Baseline, Weeks 3, 4, 5, 6 and 7
Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Weeks 3, 4, 5, 6 and 7
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.
Time frame: Baseline, Weeks 3, 4, 5, 6 and 7
Single-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Weeks 3, 4, 5, 6 and 7
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.
Time frame: Baseline, Weeks 3, 4, 5, 6 and 7
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Sleep Time at Weeks 11, 12, 13, 14 and 15
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.
Time frame: Baseline, Weeks 11, 12, 13, 14 and 15
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Weeks 11, 12, 13, 14 and 15
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).
Time frame: Baseline, Weeks 11, 12, 13, 14 and 15
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Weeks 11, 12, 13, 14 and 15
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.
Time frame: Baseline, Weeks 11, 12, 13, 14 and 15
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Weeks 11, 12, 13, 14 and 15
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.
Time frame: Baseline, Weeks 11, 12, 13, 14 and 15
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Weeks 11, 12, 13, 14 and 15
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.
Time frame: Baseline, Weeks 11, 12, 13, 14 and 15
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment- Total Sleep Time at Double Blind End Point Visit (Week 19)
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.
Time frame: Baseline, Double blind end point visit (Week 19)
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Double Blind End Point Visit (Week 19)
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).
Time frame: Baseline, Double blind end point visit (Week 19)
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Double Blind End Point Visit (Week 19)
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.
Time frame: Baseline, Double blind end point visit (Week 19)
Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Double Blind End Point Visit (Week 19)
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.
Time frame: Baseline, Double blind end point visit (Week 19)
Number of Participants With Suicidal Ideation Throughout the Study Assessed by Columbia Classification Algorithm of Suicide Assessment (C-CASA)
C-CASA was used to categorize and summarize results from the Sheehan Suicidality Tracking Scale (S-STS) and the Columbia Suicidality Severity Rating Scale (C-SSRS). S-STS was an 8-item prospective rating scale that tracked treatment-emergent suicidal ideation and behaviors. Items 1a, 2 to 6, 7a, 8 were scored on a 5-point Likert scale (ranges 0 \[not at all\] to 4 \[extremely\]). Items 1, 1b, and 7 required yes or no responses. S-STS total score range 0-30. Lower score=reduced suicidal tendency. C-SSRS was a participant rated questionnaire to assess suicidal ideation, suicidal behavior, actual attempts (yes or no responses), and intensity of ideation (rated 1=low severity to 5=high severity). Responses on S-STS or C-SSRS were mapped to C-CASA categories as: Completed suicide; suicide attempt; preparatory acts; suicide ideation; self-injurious behavior, intent unknown; not enough information; self-injurious behavior, no suicide intent; other, no deliberate self harm.
Time frame: Week 1 to Week 7 and Week 11 to Week 20
The study was performed in 4 countries at 50 centers.
| Milestone | Pregabalin (Single Blind Phase) | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|---|
| Started | 441 | 0 | 0 |
| Completed | 320 | 0 | 0 |
| Not completed | 121 | 0 | 0 |
| Withdrew: Lack of efficacy | 37 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 0 | 0 |
| Withdrew: Withdrawal by subject | 15 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 |
| Withdrew: Adverse event | 52 | 0 | 0 |
| Withdrew: (failed to meet dosing requirement) | 1 | 0 | 0 |
| Withdrew: (protocol non-compliance) | 2 | 0 | 0 |
| Withdrew: (participant request-personal reason) | 1 | 0 | 0 |
| Milestone | Pregabalin (Single Blind Phase) | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|---|
| Started | 0 | 63 | 59 |
| Treated | 0 | 63 | 58 |
| Completed | 0 | 46 | 47 |
| Not completed | 0 | 17 | 12 |
| Withdrew: Randomized but not treated | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 6 | 9 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 6 | 1 |
| Withdrew: Adverse event | 0 | 3 | 0 |
| Withdrew: Participant request-personal reason | 0 | 1 | 0 |
The time to loss of therapeutic response (LTR) is the time to loss of pain response (\<30% pain response relative to the single-blind (SB) baseline mean pain) or withdrawal due to lack of efficacy or adverse events (in the double blind phase).
| Days | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Time to Loss of Therapeutic Response (LTR) | 58 (45 to NA) | 23 (14 to 41) |
Participants who did not maintain at least 30% pain response during the DB phase relative to baseline or were discontinued during DB due to lack of efficacy or an adverse event were considered to have a loss of therapeutic response.
| Participants | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Number of Participants With Loss of Therapeutic Response (LTR) Event | 34 | 41 |
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 numeric rating scale (NRS): 0 (no pain) to 10 (worst possible pain).
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| Week 1 | -0.9 ± 1.17 |
| Week 2 | -1.5 ± 1.51 |
| Week 3 | -2.0 ± 1.85 |
| Week 4 | -2.3 ± 2.01 |
| Week 5 | -2.5 ± 2.00 |
| Week 6 | -2.6 ± 2.13 |
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Week 7 | -3.9 ± 1.49 | -3.0 ± 1.59 |
| Week 8 | -3.7 ± 1.72 | -2.7 ± 1.99 |
| Week 9 | -3.6 ± 2.01 | -2.8 ± 1.91 |
| Week 10 | -3.7 ± 1.96 | -2.4 ± 2.01 |
| Week 11 | -3.7 ± 2.21 | -2.6 ± 1.94 |
| Week 12 | -3.7 ± 1.98 | -2.6 ± 1.82 |
| Week 13 | -3.6 ± 2.10 | -2.6 ± 2.21 |
| Week 14 | -3.5 ± 2.11 | -2.5 ± 2.14 |
| Week 15 | -3.6 ± 2.30 | -2.6 ± 2.24 |
| Week 16 | -3.4 ± 2.22 | -2.6 ± 1.94 |
| Week 17 | -3.6 ± 2.02 | -2.5 ± 1.82 |
| Week 18 | -3.4 ± 2.53 | -2.5 ± 1.93 |
| Week 19 | -3.4 ± 2.59 | -2.4 ± 2.11 |
| Week 20 | -3.0 ± 2.82 | -4.9 ± 2.74 |
Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Mean Daily Pain Score at Double Blind Endpoint Visit | -2.9 (-3.5 to -2.3) | -2.5 (-3.1 to -1.9) |
The tiredness assessment in the daily interactive voice response system (IVRS) diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| Week 1 | -0.7 ± 1.16 |
| Week 2 | -1.2 ± 1.53 |
| Week 3 | -1.6 ± 1.91 |
| Week 4 | -2.0 ± 2.08 |
| Week 5 | -2.2 ± 2.10 |
| Week 6 | -2.3 ± 2.17 |
The tiredness assessment in the daily IVRS diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Week 7 | -3.4 ± 1.74 | -3.0 ± 1.79 |
| Week 8 | -3.3 ± 1.81 | -2.8 ± 1.95 |
| Week 9 | -3.2 ± 1.93 | -2.9 ± 1.98 |
| Week 10 | -3.2 ± 2.03 | -2.6 ± 1.93 |
| Week 11 | -3.1 ± 2.16 | -2.5 ± 1.91 |
| Week 12 | -3.4 ± 1.77 | -2.5 ± 1.69 |
| Week 13 | -3.2 ± 1.82 | -2.6 ± 1.87 |
| Week 14 | -3.2 ± 2.06 | -2.5 ± 1.95 |
| Week 15 | -3.4 ± 2.15 | -2.6 ± 1.96 |
| Week 16 | -3.1 ± 2.15 | -2.7 ± 1.84 |
| Week 17 | -3.4 ± 1.88 | -2.5 ± 1.96 |
| Week 18 | -3.2 ± 2.24 | -2.4 ± 1.82 |
| Week 19 | -3.1 ± 2.23 | -2.4 ± 1.96 |
| Week 20 | -2.7 ± 2.42 | -4.9 ± 1.48 |
The tiredness assessment in the daily IVRS diary consists of an 11-point NRS ranging from zero (not tired) to 10 (extremely tired). Participants rate their tiredness due to fibromyalgia during the past 24 hours by choosing the appropriate number between 0 (not tired) and 10 (extremely tired).
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Average Daily Tiredness Score at Double Blind Endpoint Visit | -2.6 (-3.2 to -2.0) | -2.5 (-3.1 to -1.9) |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
| Minutes | Pregabalin (Single Blind Phase) |
|---|---|
| Subjective Wake after Sleep Onset (Week 1) | -19.1 ± 45.90 |
| Subjective Wake after Sleep Onset (Week 2) | -22.4 ± 50.22 |
| Subjective Wake after Sleep Onset (Week 3) | -25.0 ± 64.57 |
| Subjective Wake after Sleep Onset (Week 4) | -27.5 ± 62.58 |
| Subjective Wake after Sleep Onset (Week 5) | -31.4 ± 57.37 |
| Subjective Wake after Sleep Onset (Week 6) | -32.8 ± 59.51 |
| Subjective Latency to Sleep Onset (Week 1) | -10.3 ± 42.35 |
| Subjective Latency to Sleep Onset (Week 2) | -13.0 ± 43.25 |
| Subjective Latency to Sleep Onset (Week 3) | -15.5 ± 49.01 |
| Subjective Latency to Sleep Onset (Week 4) | -19.6 ± 49.84 |
| Subjective Latency to Sleep Onset (Week 5) | -20.0 ± 52.32 |
| Subjective Latency to Sleep Onset (Week 6) | -16.9 ± 47.34 |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
| Number of times the participant awakened | Pregabalin (Single Blind Phase) |
|---|---|
| Subjective No.of Awakenings after Sleep (Week 1) | -0.8 ± 1.28 |
| Subjective No.of Awakenings after Sleep (Week 2) | -1.0 ± 1.50 |
| Subjective No.of Awakenings after Sleep (Week 3) | -1.1 ± 1.54 |
| Subjective No.of Awakenings after Sleep (Week 4) | -1.1 ± 1.44 |
| Subjective No.of Awakenings after Sleep (Week 5) | -1.2 ± 1.70 |
| Subjective No.of Awakenings after Sleep (Week 6) | -1.2 ± 1.52 |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
| Hours | Pregabalin (Single Blind Phase) |
|---|---|
| Subjective Total Sleep Time (Week 1) | 0.6 ± 0.93 |
| Subjective Total Sleep Time (Week 2) | 0.6 ± 0.96 |
| Subjective Total Sleep Time (Week 3) | 0.6 ± 1.00 |
| Subjective Total Sleep Time (Week 4) | 0.7 ± 0.94 |
| Subjective Total Sleep Time (Week 5) | 0.7 ± 1.00 |
| Subjective Total Sleep Time (Week 6) | 0.7 ± 1.08 |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses at each week was therefore 0 (very poor) -10 (excellent), where higher scores indicated better quality of sleep.
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| Sleep quality (Week 1) | 1.0 ± 1.35 |
| Sleep quality (Week 2) | 1.2 ± 1.43 |
| Sleep quality (Week 3) | 1.5 ± 1.75 |
| Sleep quality (Week 4) | 1.6 ± 1.79 |
| Sleep quality (Week 5) | 1.7 ± 1.82 |
| Sleep quality (Week 6) | 1.7 ± 1.89 |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
| Minutes | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Subjective Wake after Sleep Onset (Week 7) | -27.8 ± 37.29 | -32.0 ± 50.47 |
| Subjective Wake after Sleep Onset (Week 8) | -27.4 ± 39.39 | -28.0 ± 56.99 |
| Subjective Wake after Sleep Onset (Week 9) | -27.0 ± 40.12 | -33.2 ± 56.45 |
| Subjective Wake after Sleep Onset (Week 10) | -26.9 ± 38.92 | -26.2 ± 68.24 |
| Subjective Wake after Sleep Onset (Week 11) | -29.0 ± 44.80 | -37.4 ± 56.79 |
| Subjective Wake after Sleep Onset (Week 12) | -26.0 ± 46.00 | -31.0 ± 43.96 |
| Subjective Wake after Sleep Onset (Week 13) | -22.8 ± 37.78 | -31.4 ± 50.08 |
| Subjective Wake after Sleep Onset (Week 14) | -27.0 ± 39.87 | -43.3 ± 54.45 |
| Subjective Wake after Sleep Onset (Week 15) | -31.7 ± 38.37 | -35.1 ± 56.47 |
| Subjective Wake after Sleep Onset (Week 16) | -25.9 ± 41.95 | -35.0 ± 52.67 |
| Subjective Wake after Sleep Onset (Week 17) | -31.5 ± 34.29 | -36.2 ± 58.67 |
| Subjective Wake after Sleep Onset (Week 18) | -32.4 ± 36.37 | -37.3 ± 56.67 |
| Subjective Wake after Sleep Onset (Week 19) | -27.3 ± 52.27 | -23.1 ± 46.28 |
| Subjective Wake after Sleep Onset (Week 20) | -22.5 ± 11.03 | -7.1 ± 11.15 |
| Subjective Latency to Sleep Onset (Week 7) | -15.6 ± 55.67 | -19.1 ± 41.02 |
| Subjective Latency to Sleep Onset (Week 8) | -19.1 ± 29.70 | -12.3 ± 42.83 |
| Subjective Latency to Sleep Onset (Week 9) | -18.4 ± 34.03 | -16.0 ± 50.97 |
| Subjective Latency to Sleep Onset (Week 10) | -19.5 ± 29.40 | -18.0 ± 43.83 |
| Latency to Sleep Onset (Week 11) | -18.5 ± 22.40 | -18.0 ± 47.82 |
| Subjective Latency to Sleep Onset (Week 12) | -16.3 ± 26.04 | -18.8 ± 40.31 |
| Subjective Latency to Sleep Onset (Week 13) | -17.5 ± 20.79 | -16.8 ± 36.51 |
| Subjective Latency to Sleep Onset (Week 14) | -20.8 ± 25.58 | -21.8 ± 44.03 |
| Subjective Latency to Sleep Onset (Week 15) | -19.4 ± 20.25 | -19.1 ± 42.55 |
| Subjective Latency to Sleep Onset (Week 16) | -15.8 ± 31.85 | -20.9 ± 42.18 |
| Subjective Latency to Sleep Onset (Week 17) | -23.1 ± 23.09 | -20.9 ± 49.30 |
| Subjective Latency to Sleep Onset (Week 18) | -16.3 ± 24.52 | -18.7 ± 46.23 |
| Subjective Latency to Sleep Onset (Week 19) | -16.7 ± 29.38 | -19.5 ± 50.89 |
| Subjective Latency to Sleep Onset (Week 20) | 23.0 ± 84.31 | -28.7 ± 8.00 |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
| Number of times the participant awakened | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Subjective No.of Awakenings after Sleep (Week 7) | -1.1 ± 1.39 | -1.0 ± 1.30 |
| Subjective No.of Awakenings after Sleep (Week 8) | -1.2 ± 1.23 | -0.8 ± 1.27 |
| Subjective No.of Awakenings after Sleep (Week 9) | -1.2 ± 0.94 | -1.1 ± 1.12 |
| Subjective No.of Awakenings after Sleep (Week 10) | -1.2 ± 1.10 | -0.9 ± 1.16 |
| Subjective No.of Awakenings after Sleep (Week 11) | -1.1 ± 1.40 | -0.9 ± 1.18 |
| Subjective No.of Awakenings after Sleep (Week 12) | -1.1 ± 1.50 | -0.8 ± 1.00 |
| Subjective No.of Awakenings after Sleep (Week 13) | -1.0 ± 1.02 | -1.0 ± 1.13 |
| Subjective No.of Awakenings after Sleep (Week 14) | -1.0 ± 1.06 | -1.1 ± 1.07 |
| Subjective No.of Awakenings after Sleep (Week 15) | -0.8 ± 2.20 | -1.1 ± 1.21 |
| Subjective No.of Awakenings after Sleep (Week 16) | -1.0 ± 1.10 | -1.0 ± 1.18 |
| Subjective No.of Awakenings after Sleep (Week 17) | -1.2 ± 0.92 | -0.9 ± 1.25 |
| Subjective No.of Awakenings after Sleep (Week 18) | -1.1 ± 1.14 | -1.0 ± 1.28 |
| Subjective No.of Awakenings after Sleep (Week 19) | -0.7 ± 2.63 | -0.9 ± 1.32 |
| Subjective No.of Awakenings after Sleep (Week 20) | -1.5 ± 1.14 | -1.5 ± 0.95 |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Subjective total sleep time was the subjective estimate of the total amount of time the participant was asleep after lights out until final awakening.
| Hours | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Subjective Total Sleep Time (Week 7) | 0.7 ± 1.00 | 0.5 ± 1.10 |
| Subjective Total Sleep Time (Week 8) | 0.9 ± 0.89 | 0.6 ± 1.25 |
| Subjective Total Sleep Time (Week 9) | 0.8 ± 1.00 | 0.5 ± 1.10 |
| Subjective Total Sleep Time (Week 10) | 0.9 ± 1.07 | 0.5 ± 1.01 |
| Subjective Total Sleep Time (Week 11) | 0.9 ± 0.86 | 0.6 ± 1.08 |
| Subjective Total Sleep Time (Week 12) | 0.8 ± 1.01 | 0.5 ± 1.13 |
| Subjective Total Sleep Time (Week 13) | 0.7 ± 0.93 | 0.6 ± 0.95 |
| Subjective Total Sleep Time (Week 14) | 0.9 ± 1.31 | 0.7 ± 1.17 |
| Subjective Total Sleep Time (Week 15) | 0.7 ± 0.90 | 0.7 ± 1.22 |
| Subjective Total Sleep Time (Week 16) | 0.7 ± 0.94 | 0.7 ± 1.04 |
| Subjective Total Sleep Time (Week 17) | 0.7 ± 0.85 | 0.7 ± 1.08 |
| Subjective Total Sleep Time (Week 18) | 0.6 ± 0.85 | 0.5 ± 1.23 |
| Subjective Total Sleep Time (Week 19) | 0.5 ± 1.10 | 0.6 ± 1.15 |
| Subjective Total Sleep Time (Week 20) | -0.1 ± 1.02 | 0.5 ± 0.41 |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses at each week was therefore 0 (very poor) -10 (excellent), where higher scores indicated better quality of sleep.
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Sleep Quality (Week 7) | 1.9 ± 1.69 | 1.9 ± 1.62 |
| Sleep Quality (Week 8) | 2.0 ± 1.61 | 1.7 ± 1.71 |
| Sleep Quality (Week 9) | 2.1 ± 1.47 | 1.8 ± 1.66 |
| Sleep Quality (Week 10) | 2.2 ± 1.70 | 1.7 ± 1.74 |
| Sleep Quality (Week 11) | 2.3 ± 1.78 | 1.7 ± 1.63 |
| Sleep Quality (Week 12) | 2.1 ± 1.66 | 1.7 ± 1.65 |
| Sleep Quality (Week 13) | 1.9 ± 1.72 | 1.9 ± 1.63 |
| Sleep Quality (Week 14) N=48,43 | 2.2 ± 1.69 | 2.1 ± 1.73 |
| Sleep Quality (Week 15) | 2.2 ± 1.76 | 2.0 ± 1.64 |
| Sleep Quality (Week 16) | 1.9 ± 1.87 | 1.9 ± 1.68 |
| Sleep Quality (Week 17) | 2.2 ± 1.71 | 1.9 ± 1.72 |
| Sleep Quality (Week 18) | 2.1 ± 1.64 | 1.8 ± 1.71 |
| Sleep Quality (Week 19) | 2.0 ± 1.77 | 1.5 ± 1.55 |
| Sleep Quality (Week 20) | 3.1 ± 1.23 | 3.3 ± 0.45 |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
| Minutes | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Subjective Wake after Sleep Onset | -26.2 (-36.6 to -15.8) | -20.6 (-30.7 to -10.5) |
| Subjective Latency to Sleep Onset | -10.6 (-24.2 to 3.0) | -11.9 (-25.0 to 1.3) |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
| Number of times the participant awakened | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Number of Awakenings After Sleep Onset at Double Blind Endpoint Visit | -0.5 (-1.1 to 0.1) | -0.8 (-1.4 to -0.2) |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night.
| Hours | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Subjective Total Sleep Time at Double Blind Endpoint Visit | 0.6 (0.3 to 0.9) | 0.4 (0.1 to 0.7) |
The SSQ is designed to capture subjective behavior in participants with disrupted sleep. Participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Participants rated quality of sleep during the past night by selecting a number between 0 (very poor) and 10 (excellent).
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Daily Subjective Sleep Questionnaire (SSQ) - Sleep Quality at Double Blind Endpoint Visit | 1.9 (1.4 to 2.4) | 1.4 (1.0 to 1.9) |
Weekly pain scores were calculated from the daily pain diary. Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| Single-Blind Phase: Change From Baseline in Weekly Pain Score at Week 6 (1 Week Recall Period) | -1.6 ± 2.18 |
Weekly pain scores were calculated from the daily pain diary. Daily Pain Score: Day 1 pain intensity over past 24 hours recorded on waking every morning. 0-10 NRS: 0 (no pain) to 10 (worst possible pain).
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Weekly Pain Score at Week 19 (1 Week Recall Period) | -3.1 (-3.8 to -2.4) | -2.4 (-3.1 to -1.7) |
The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| Sleep disturbance | -21.8 ± 24.82 |
| Snoring | -1.0 ± 24.94 |
| Awakening Short of Breath/with a Headache | -11.0 ± 30.59 |
| Sleep adequacy | 18.9 ± 31.17 |
| Somnolence | -3.6 ± 24.87 |
| Sleep Problems Index I | -16.1 ± 21.62 |
| Sleep Problems Index II | -15.9 ± 20.44 |
The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.
| hours | Pregabalin (Single Blind Phase) |
|---|---|
| Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 6- Quantity of Sleep | 0.7 ± 1.33 |
The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Sleep disturbance | -25.4 (-32.0 to -18.8) | -15.5 (-21.8 to -9.1) |
| Snoring | -2.4 (-5.2 to 9.9) | -2.9 (-10.1 to 4.3) |
| Awakening Short of Breath/with a Headache | -8.1 (-13.5 to -2.7) | -4.2 (-9.3 to -0.9) |
| Sleep adequacy | 23.9 (16.0 to 31.9) | 17.1 (9.5 to 24.8) |
| Somnolence | -11.9 (-17.8 to -5.9) | -6.6 (-12.4 to -0.9) |
| Sleep Problems Index I | -19.5 (-25.0 to -13.9) | -13.7 (-19.0 to -8.3) |
| Sleep Problems Index II | -19.7 (-25.4 to -14.0) | -14.0 (-19.5 to -8.6) |
The MOS-SS is a validated self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) and two overall sleep problems indices assessing sleep over the past week. Score range for Sleep Disturbance (SD), sleep adequacy (SA), snoring, somnolence, awakening short of breath/headache was 0-100, where higher score=greater SD; greater SA; greater snoring; greater somnolence; greater shortness of breath/headache respectively. Quantity of Sleep (range-0 to 24 hours; higher scores/hours=greater quantity of sleep). Sleep Problem Index I and II: Score Range=0 to 100; higher scores =greater sleep problems. Optimal Sleep (assessed as yes or no), 'Yes' =optimal sleep (average 7-8 hours/night); 'No' =not optimal sleep.
| hours | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 19- Quantity of Sleep | 0.7 (0.4 to 1.0) | 0.5 (0.2 to 0.8) |
PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).
| Participants | Pregabalin (Single Blind Phase) |
|---|---|
| Very Much Improved | 24 |
| Much Improved | 77 |
| Minimally Improved | 103 |
| No Change | 46 |
| Minimally Worse | 16 |
| Much Worse | 18 |
| Very Much Worse | 5 |
PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).
| Participants | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Very Much Improved | 7 | 7 |
| Much Improved | 15 | 11 |
| Minimally Improved | 14 | 12 |
| No Change | 9 | 11 |
| Minimally Worse | 7 | 6 |
| Much Worse | 7 | 8 |
| Very Much Worse | 1 | 2 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100. Higher scores indicated a better health-related quality of life.
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| SF-36 Physical Functioning | 14.0 ± 19.89 |
| SF-36 Role-Physical | 17.8 ± 27.38 |
| SF-36 Pain Index | 20.7 ± 22.07 |
| SF-36 General Health Perceptions | 8.5 ± 17.96 |
| SF-36 Vitality | 18.2 ± 24.35 |
| SF-36 Social Functioning | 12.9 ± 28.19 |
| SF-36 Role-Emotional | 8.6 ± 29.40 |
| SF-36 Mental Health Index | 7.9 ± 18.94 |
| Physical Component Score | 7.2 ± 8.75 |
| Mental Component Score | 4.5 ± 11.78 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100. Higher scores indicated a better health-related quality of life.
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| SF-36 Physical Functioning | 12.4 (6.4 to 18.4) | 13.7 (8.0 to 19.5) |
| SF-36 Role-Physical | 18.9 (11.7 to 26.0) | 16.2 (9.4 to 23.1) |
| SF-36 Pain Index | 19.2 (12.5 to 26.0) | 16.0 (9.5 to 22.5) |
| SF-36 General Health Perceptions | 3.3 (-1.8 to 8.3) | 9.3 (4.5 to 14.2) |
| SF-36 Vitality | 12.2 (5.3 to 19.1) | 15.7 (9.1 to 22.3) |
| SF-36 Social Functioning | 13.3 (7.0 to 19.6) | 13.5 (7.4 to 19.5) |
| SF-36 Role-Emotional | 3.8 (-4.1 to 11.7) | 2.2 (-5.4 to 9.8) |
| SF-36 Mental Health Index | 6.6 (1.4 to 11.7) | 5.2 (0.3 to 10.2) |
| Physical Component Score | 6.8 (4.2 to 9.4) | 7.2 (4.7 to 9.7) |
| Mental Component Score | 2.6 (-0.6 to 5.8) | 2.4 (-0.7 to 5.5) |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| HADS-A Anxiety scale | -1.8 ± 3.47 |
| HADS-D Depression scale | -1.5 ± 3.62 |
HADS: participant rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| HADS-A Anxiety scale | -0.7 (-1.7 to 0.4) | -1.6 (-2.6 to -0.6) |
| HADS-D Depression scale | -1.4 (-2.3 to -0.4) | -1.1 (-2.0 to -0.2) |
The FIQ is a 20-item self-administered questionnaire. FIQ contains 10 subscales, which are combined to yield a total score. There are 11 questions that are related specifically to physical functioning (item 1). The remaining questions assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. The FIQ is scored from 0 to 100, with higher scores indicating more impairment.
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| Item 1: Physical activities | -0.9 ± 2.14 |
| Item 2: Feel good | -2.2 ± 3.33 |
| Item 3: Work missed | -0.5 ± 2.42 |
| Item 4: Do job | -1.5 ± 2.72 |
| Item 5: Pain | -1.6 ± 2.25 |
| Item 6: Fatigue | -1.4 ± 2.43 |
| Item 7: Rested | -1.7 ± 2.65 |
| Item 8: Stiffness | -1.8 ± 2.65 |
| Item 9: Anxiety | -1.2 ± 2.95 |
| Item 10: Depression | -0.6 ± 2.75 |
| Total Score | -13.4 ± 16.71 |
The FIQ is a 20-item self-administered questionnaire. FIQ contains 10 subscales, which are combined to yield a total score. There are 11 questions that are related specifically to physical functioning (item 1). The remaining questions assess pain, fatigue, stiffness, difficulty working, and symptoms of anxiousness and depression. The FIQ is scored from 0 to 100, with higher scores indicating more impairment.
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Item 1: Physical activities | -1.0 (-1.6 to -0.4) | -1.3 (-1.9 to -0.8) |
| Item 2: feel good | -3.0 (-3.9 to -2.1) | -3.2 (-4.1 to -2.3) |
| Item 3: Work missed | -1.2 (-1.7 to -0.7) | -1.0 (-1.5 to -0.5) |
| Item 4: Do job | -2.1 (-3.0 to -1.3) | -2.2 (-3.0 to -1.4) |
| Item 5: Pain | -2.7 (-3.4 to -2.0) | -2.2 (-2.8 to -1.5) |
| Item 6: Fatigue | -2.3 (-3.0 to -1.6) | -2.4 (-3.0 to -1.7) |
| Item 7: Rested | -2.6 (-3.4 to -1.8) | -2.2 (-3.0 to -1.4) |
| Item 8: Stiffness | -2.4 (-3.2 to -1.6) | -2.2 (-3.0 to -1.4) |
| Item 9: Anxiety | -1.8 (-2.6 to -1.0) | -1.7 (-2.5 to -0.9) |
| Item 10: Depression | -0.7 (-1.4 to -0.0) | -0.7 (-1.3 to 0.0) |
| Total Score | -19.6 (-25.3 to -13.9) | -19.1 (-24.6 to -13.7) |
The MFI is a 20-item, self-administered questionnaire designed to measure the following dimensions of fatigue: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Items are summed to form subscale scores; there is no overall score. The score range is from 4 to 20, where higher scores indicate greater dysfunction.
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| General fatigue | -0.2 ± 2.47 |
| Physical fatigue | 0.1 ± 2.67 |
| Reduced activity | -0.2 ± 2.55 |
| Reduced motivation | 0.2 ± 2.71 |
| Mental fatigue | -0.1 ± 2.17 |
The MFI is a 20-item, self-administered questionnaire designed to measure the following dimensions of fatigue: general fatigue, physical fatigue, mental fatigue, reduced motivation, and reduced activity. Items are summed to form subscale scores; there is no overall score. The score range is from 4 to 20, where higher scores indicate greater dysfunction.
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| General fatigue | 0.1 (-0.4 to 0.6) | -0.1 (-0.6 to 0.3) |
| Physical fatigue | -0.1 (-0.6 to 0.5) | 0.2 (-0.3 to 0.7) |
| Reduced activity | 0.0 (-0.5 to 0.6) | -0.3 (-0.7 to 0.2) |
| Reduced motivation | 1.0 (0.4 to 1.5) | 0.3 (-0.2 to 0.8) |
| Mental fatigue | -0.1 (-0.5 to 0.3) | 0.1 (-0.3 to 0.4) |
The questionnaire consists of 3 single-item measures designed to captures the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.
| Participants | Pregabalin (Single Blind Phase) |
|---|---|
| Benefit from treatment-No | 69 |
| Benefit from treatment-Little benefit | 137 |
| Benefit from treatment-much benefit | 211 |
| Satisfaction from treatment-very dissatisfied | 52 |
| Satisfaction from treatment-a little dissatisfied | 59 |
| Satisfaction from treatment-a little satisfied | 103 |
| Satisfaction from treatment-very satisfied | 203 |
| Willing to continue treatment-very unwilling | 68 |
| Willing to continue treatment-little unwilling | 33 |
| Willing to continue treatment-little bit willing | 49 |
| Willing to continue treatment-very willing | 266 |
The questionnaire consists of 3 single-item measures designed to captures the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy.
| Participants | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Benefit from treatment-No | 3 | 11 |
| Benefit from treatment-Little benefit | 15 | 16 |
| Benefit from treatment-much benefit | 41 | 30 |
| Satisfaction from treatment-very dissatisfied | 4 | 6 |
| Satisfaction from treatment-a little dissatisfied | 10 | 8 |
| Satisfaction from treatment-a little satisfied | 10 | 13 |
| Satisfaction from treatment-very satisfied | 36 | 30 |
| Willing to continue treatment-very unwilling | 8 | 4 |
| Willing to continue treatment-little unwilling | 6 | 8 |
| Willing to continue treatment-little bit willing | 9 | 11 |
| Willing to continue treatment-very willing | 37 | 34 |
WPAI: 6 question participant rated questionnaire to determine the degree to which disease state affected work productivity while at work and affected activities outside of work. Subscale scores include percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.
| Units on a scale | Pregabalin (Single Blind Phase) |
|---|---|
| Percent Work Time Missed | -5.8 ± 48.69 |
| Percent Impairment While Working | -10.0 ± 31.29 |
| Percent Activity Impairment | -13.5 ± 25.88 |
| Percent Overall Work Impairment | -12.3 ± 27.62 |
WPAI: 6 question participant rated questionnaire to determine the degree to which disease state affected work productivity while at work and affected activities outside of work. Subscale scores include percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Scores scaled as 0 (not affected/no impairment) to 10 (completely affected/impaired). Higher scores indicated greater impairment and less productivity.
| Units on a scale | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Percent Work Time Missed | -7.3 (-21.3 to 6.7) | -26.7 (-41.0 to -12.3) |
| Percent Impairment While Working | -14.0 (-19.7 to -8.2) | -15.0 (-20.8 to -9.3) |
| Percent Activity Impairment | -16.4 (-19.0 to -13.7) | -19.6 (-22.1 to -17.0) |
| Percent Overall Work Impairment | -15.9 (-18.7 to -13.1) | -17.5 (-20.2 to -14.8) |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.
| Hours | Pregabalin (Single Blind Phase) |
|---|---|
| Total Sleep Time (Week 3) | -0.1 ± 0.94 |
| Total Sleep Time (Week 4) | 0.4 ± 0.99 |
| Total Sleep Time (Week 5) | 0.3 ± 1.02 |
| Total Sleep Time (Week 6) | 0.3 ± 1.15 |
| Total Sleep Time (Week 7) | 0.6 ± 1.10 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).
| Minutes | Pregabalin (Single Blind Phase) |
|---|---|
| Minutes of Interrupted Sleep (Week 3) | -5.3 ± 12.63 |
| Minutes of Interrupted Sleep (Week 4) | -5.9 ± 16.10 |
| Minutes of Interrupted Sleep (Week 5) | -7.0 ± 15.66 |
| Minutes of Interrupted Sleep (Week 6) | -6.6 ± 16.12 |
| Minutes of Interrupted Sleep (Week 7) | 0.7 ± 19.43 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.
| Percentage of immobile bouts | Pregabalin (Single Blind Phase) |
|---|---|
| Sleep Fragmentation Index (Week 3) | -0.8 ± 5.27 |
| Sleep Fragmentation Index (Week 4) | -2.5 ± 5.45 |
| Sleep Fragmentation Index (Week 5) | -2.8 ± 5.27 |
| Sleep Fragmentation Index (Week 6) | -2.6 ± 5.63 |
| Sleep Fragmentation Index (Week 7) | 0.7 ± 5.85 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.
| Counts of total daytime activity | Pregabalin (Single Blind Phase) |
|---|---|
| Total daytime activity (Week 3) | 10264.3 ± 90090.07 |
| Total daytime activity (Week 4) | 10588.1 ± 59150.38 |
| Total daytime activity (Week 5) | 8635.8 ± 54823.64 |
| Total daytime activity (Week 6) | 7134.2 ± 58221.22 |
| Total daytime activity (Week 7) | 18420.7 ± 61725.84 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.
| Percent of daytime | Pregabalin (Single Blind Phase) |
|---|---|
| Percent Sedentary (Week 3) | 0.7 ± 6.66 |
| Percent Sedentary (Week 4) | 0.7 ± 5.61 |
| Percent Sedentary (Week 5) | 0.6 ± 5.62 |
| Percent Sedentary (Week 6) | 0.3 ± 6.07 |
| Percent Sedentary (Week 7) | 0.2 ± 5.51 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.
| Hours | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Total Sleep Time (Week 11) | 0.5 ± 0.91 | 0.0 ± 1.53 |
| Total Sleep Time (Week 12) | 0.5 ± 1.23 | 0.1 ± 1.01 |
| Total Sleep Time (Week 13) | 0.4 ± 1.15 | 0.1 ± 1.15 |
| Total Sleep Time (Week 14) | 0.4 ± 1.02 | 0.1 ± 1.14 |
| Total Sleep Time (Week 15) | 0.2 ± 0.91 | 0.3 ± 1.13 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).
| Minutes | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Minutes of Interrupted Sleep (Week 11) | -9.0 ± 10.27 | 2.5 ± 18.97 |
| Minutes of Interrupted Sleep (Week 12) | -3.0 ± 14.77 | -1.7 ± 14.10 |
| Minutes of Interrupted Sleep (Week 13) | -3.0 ± 20.33 | 0.4 ± 14.14 |
| Minutes of Interrupted Sleep (Week 14) | -3.2 ± 19.12 | -1.8 ± 13.19 |
| Minutes of Interrupted Sleep (Week 15) | -0.4 ± 25.03 | -0.5 ± 13.73 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.
| Percentage of immobile bouts | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Sleep Fragmentation Index (Week 11) | -4.4 ± 5.53 | 0.1 ± 5.17 |
| Sleep Fragmentation Index (Week 12) | -2.8 ± 5.91 | -0.4 ± 6.29 |
| Sleep Fragmentation Index (Week 13) | -2.2 ± 7.28 | -0.3 ± 5.23 |
| Sleep Fragmentation Index (Week 14) | -2.4 ± 7.32 | -0.6 ± 4.75 |
| Sleep Fragmentation Index (Week 15) | -0.9 ± 7.41 | -0.9 ± 5.19 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.
| Counts of total daytime activity | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Total daytime activity (Week 11) | -1894.1 ± 46879.81 | -2083.9 ± 40939.67 |
| Total daytime activity ((Week 12) | -50.7 ± 50114.87 | -6691.1 ± 47353.03 |
| Total daytime activity ((Week 13) | -4362.4 ± 51922.75 | 521.8 ± 46996.71 |
| Total daytime activity ((Week 14) | -179.7 ± 55858.35 | -4523.8 ± 52629.95 |
| Total daytime activity ((Week 15) | -4138.3 ± 54924.02 | -4649.4 ± 58121.16 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.
| Percent of daytime | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Percent Sedentary (Week 11) | -0.7 ± 7.72 | 1.1 ± 6.69 |
| Percent Sedentary (Week 12) | -0.8 ± 5.66 | -1.4 ± 6.15 |
| Percent Sedentary (Week 13) | -1.3 ± 5.41 | -0.9 ± 6.15 |
| Percent Sedentary (Week 14) | -2.1 ± 6.56 | -1.1 ± 7.27 |
| Percent Sedentary (Week 15) | -1.5 ± 5.21 | -1.4 ± 6.56 |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total sleep time = number of minutes asleep between time of sleep onset to morning awakening.
| Hours | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment- Total Sleep Time at Double Blind End Point Visit (Week 19) | 0.5 (0.1 to 0.9) | 0.1 (-0.3 to 0.5) |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Minutes of interrupted sleep = minutes awake after sleep onset (analogous to wake-time after sleep onset from polysomnography measurements).
| Minutes | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Minutes of Interrupted Sleep at Double Blind End Point Visit (Week 19) | -3.5 (-10.0 to 2.9) | -2.3 (-8.8 to 4.1) |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Sleep fragmentation index = a measure of sleep relatedness. Sleep fragmentation index calculated from analysis of the periods that participant was not moving (immobile bouts). It is number of immobile bouts that were exactly 1 minute long divided by total number of immobile bouts. Value ranges from 0-100 percent, with low number representing more restful sleep.
| Percentage of immobile bouts | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Sleep Fragmentation Index at Double Blind End Point Visit (Week 19) | -2.5 (-4.6 to -0.5) | -0.6 (-2.6 to 1.4) |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Total daytime activity = total activity "counts" during the day.
| Counts of total daytime activity | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Total Daytime Activity at Double Blind End Point Visit (Week 19) | -182.7 (-20143.1 to 19777.7) | -6672.2 (-26663.5 to 13319.1) |
Actigraphy was assessed with an accelerometer that was worn on the wrist. The accelerometer was programmed to record movements. This information was used to calculate several endpoints reflecting daytime activity, and sleep quality and duration. Percent sedentary = percent of daytime spent in sedentary activities as determined by the activity counts measured each minute.
| Percent of daytime | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|
| Double-Blind Phase: Change From Baseline in Actigraphy Functional/Sleep Assessment - Percent Sedentary at Double Blind End Point Visit (Week 19) | -1.4 (-3.6 to 0.8) | -2.0 (-4.2 to 0.2) |
C-CASA was used to categorize and summarize results from the Sheehan Suicidality Tracking Scale (S-STS) and the Columbia Suicidality Severity Rating Scale (C-SSRS). S-STS was an 8-item prospective rating scale that tracked treatment-emergent suicidal ideation and behaviors. Items 1a, 2 to 6, 7a, 8 were scored on a 5-point Likert scale (ranges 0 \[not at all\] to 4 \[extremely\]). Items 1, 1b, and 7 required yes or no responses. S-STS total score range 0-30. Lower score=reduced suicidal tendency. C-SSRS was a participant rated questionnaire to assess suicidal ideation, suicidal behavior, actual attempts (yes or no responses), and intensity of ideation (rated 1=low severity to 5=high severity). Responses on S-STS or C-SSRS were mapped to C-CASA categories as: Completed suicide; suicide attempt; preparatory acts; suicide ideation; self-injurious behavior, intent unknown; not enough information; self-injurious behavior, no suicide intent; other, no deliberate self harm.
| Participants | Pregabalin (Single Blind Phase) | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|---|
| Week 1 | 5 | — | — |
| Week 2 | 6 | — | — |
| Week 3 | 4 | — | — |
| Week 6 | 16 | — | — |
| Week 7 | 10 | — | — |
| Week 11 | — | 3 | 0 |
| Week 15 | — | 1 | 1 |
| Week 19 | — | 1 | 3 |
| Week 20 | — | 1 | 1 |
Collected over From time that the participant provided informed consent through and including 28 calender days after the last administration of the investigational product (up to Week 20). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin (Single Blind Phase) | — | 5/441 (1.1%) | 353/441 (80%) |
| Pregabalin (Double Blind Phase) | — | 2/63 (3.2%) | 34/63 (54%) |
| Placebo (Double Blind Phase) | — | 0/58 (0%) | 27/58 (46.6%) |
| Event | Pregabalin (Single Blind Phase) | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|---|
| VertigoEar and labyrinth disorders | 0/441 | 1/63 | 0/58 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/441 | 1/63 | 0/58 |
| GlossitisGastrointestinal disorders | 1/441 | 0/63 | 0/58 |
| Chest painGeneral disorders | 1/441 | 0/63 | 0/58 |
| CellulitisInfections and infestations | 1/441 | 0/63 | 0/58 |
| PneumoniaInfections and infestations | 1/441 | 0/63 | 0/58 |
| HypertensionInvestigations | 1/441 | 0/63 | 0/58 |
| Post-traumatic stress disorderPsychiatric disorders | 1/441 | 0/63 | 0/58 |
| Event | Pregabalin (Single Blind Phase) | Pregabalin (Double Blind Phase) | Placebo (Double Blind Phase) |
|---|---|---|---|
| DizzinessNervous system disorders | 161/441 | 2/63 | 2/58 |
| SomnolenceNervous system disorders | 105/441 | 0/63 | 0/58 |
| HeadacheNervous system disorders | 43/441 | 1/63 | 2/58 |
| FatigueGeneral disorders | 42/441 | 1/63 | 0/58 |
| Oedema peripheralGeneral disorders | 27/441 | 6/63 | 2/58 |
| NauseaGastrointestinal disorders | 41/441 | 5/63 | 0/58 |
| Weight increasedInvestigations | 30/441 | 2/63 | 1/58 |
| Vision blurredEye disorders | 29/441 | 1/63 | 0/58 |
| Dry mouthGastrointestinal disorders | 25/441 | 0/63 | 2/58 |
| Disturbance in attentionNervous system disorders | 24/441 | 0/63 | 0/58 |
Single-blind analysis set (SBAS) consisted of all participants who were enrolled into the SB phase of the study and received at least 1 dose of study medication.
| Age, Customized(Participants) | Pregabalin (Single Blind Phase) |
|---|---|
| <18 years | 0 |
| 18 - 44 years | 178 |
| 45 - 64 years | 227 |
| ≥ 65 years | 36 |
| Sex: Female, Male(Participants) | Pregabalin (Single Blind Phase) |
|---|---|
| Female | 392 |
| Male | 49 |
Ran from Mar 2011 to primary completion in Jul 2012, 16 months.
Results were first posted in Sep 2018, 6 years 2 months after primary completion. A results delay was requested in Aug 2013.
Of 17 phase 3 interventional studies under Fibromyalgia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →